INT122709

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.75
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 16
Total Number 17
Disease Relevance 5.41
Pain Relevance 2.38

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP3A4) oxidoreductase activity (CYP3A4) endoplasmic reticulum (CYP3A4)
enzyme binding (CYP3A4) lipid metabolic process (CYP3A4) cytoplasm (CYP3A4)
Anatomy Link Frequency
liver 3
intestinal lumen 1
CYP3A4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Calcium channel 4 99.80 Very High Very High Very High
cocaine 8 99.20 Very High Very High Very High
Bioavailability 18 99.12 Very High Very High Very High
antagonist 60 95.88 Very High Very High Very High
fluoxetine 4 95.88 Very High Very High Very High
withdrawal 33 89.80 High High
opiate 7 89.36 High High
colic 2 87.52 High High
headache 19 86.48 High High
Bile 2 86.48 High High
Disease Link Frequency Relevance Heat
Hyponatremia 64 96.72 Very High Very High Very High
Chronic Myeloid Leukemia 2 96.00 Very High Very High Very High
Leukopenia 2 95.76 Very High Very High Very High
Acquired Immune Deficiency Syndrome Or Hiv Infection 64 95.56 Very High Very High Very High
Uveitis 2 95.16 Very High Very High Very High
Diarrhoea 26 94.52 High High
Rhabdomyolysis 22 94.00 High High
Muscle Disease 18 90.84 High High
Fungal Infection 34 90.44 High High
Substance Withdrawal Syndrome 15 90.16 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Generally, it can be anticipated that the inactivation of CYP3A4 by various drugs would increase the bioavailability of coadministered drugs that are primarily metabolized by CYP3A4, due to intestinal and/or hepatic inhibition of CYP3A4.
Localization (metabolized) of CYP3A4 associated with bioavailability
1) Confidence 0.75 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0 Pain Relevance 0.05
However, about 10% is metabolized by CYP450 enzymes, including CYP3A4.
Localization (metabolized) of CYP3A4
2) Confidence 0.70 Published 2010 Journal Curr HIV/AIDS Rep Section Body Doc Link PMC2892618 Disease Relevance 0.41 Pain Relevance 0.98
Clinicians must also be aware of drug interactions, particularly drugs that are metabolized by cytochrome CYP3A4.
Localization (metabolized) of cytochrome CYP3A4
3) Confidence 0.66 Published 2010 Journal Core evidence Section Body Doc Link PMC2899773 Disease Relevance 0.47 Pain Relevance 0.13
Dasatinib is extensively metabolized in humans by CYP3A4.
Localization (metabolized) of CYP3A4
4) Confidence 0.65 Published 2009 Journal Drug Metab. Dispos. Section Abstract Doc Link 19282395 Disease Relevance 0.10 Pain Relevance 0.10
Tacrolimus shows large variability in bioavailability after oral administration, both due to intestinal metabolism by cytochrome P450 (CYP3A4) and active secretion from enterocyte into intestinal lumen by P-glycoprotein.
Localization (secretion) of CYP3A4 in intestinal lumen associated with bioavailability
5) Confidence 0.56 Published 2004 Journal Transplant. Proc. Section Abstract Doc Link 15518758 Disease Relevance 1.14 Pain Relevance 0.13
Domperidone is highly metabolized by CYP3A4 in the liver, drug interactions related to its inhibition are expected to occur.
Localization (metabolized) of CYP3A4 in liver
6) Confidence 0.55 Published 2006 Journal BMC Pregnancy Childbirth Section Body Doc Link PMC1562444 Disease Relevance 0.70 Pain Relevance 0.21
There are a number of chemotherapy agents metabolized by CYP3A4 such as taxanes, etoposide, irinotecan, ifosfamide, imatininb, and vinca alkaloids.
Localization (metabolized) of CYP3A4
7) Confidence 0.47 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504061 Disease Relevance 0.11 Pain Relevance 0.11
Similar care should be taken with drugs with a narrow therapeutic index that are metabolized by CYP3A4 such as cyclosporine, sirolimus, and tacrolimus.
Localization (metabolized) of CYP3A4
8) Confidence 0.47 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504061 Disease Relevance 0.24 Pain Relevance 0
In general, concomitant medications which are primarily metabolized by CYP3A4 or 2D6 will tend to have increased concentrations, due to inhibition of these enzymes by the combination of darunavir and ritonavir, while medications metabolized by other CYP isoforms will have lowered concentrations due to induction of metabolism by ritonavir.12 Darunavir has been studied in combination with other anti-retroviral agents and many nonantiretroviral drugs, all of which are reported in the package insert12 and summarized in Table 4.
Localization (metabolized) of CYP3A4
9) Confidence 0.38 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2724190 Disease Relevance 0.11 Pain Relevance 0
In accordance to this, RT-PCR on liver samples showed that neither CK18, cytochrome P450 (CYP3A4) (data not shown), ?
Localization (cytochrome P450) of CYP3A4 in liver
10) Confidence 0.25 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2722022 Disease Relevance 0.22 Pain Relevance 0.03
Many lipophillic drugs are metabolized in the liver by the drug-metabolizing enzyme, cytochrome P450 (CYP).37,38 Statins are also metabolized by CYPs, for example, lipophilic statins such as simvastatin and atorvastatin are metabolized by CYP3A4, and fluvastatin by CYP2C9.39 Pitavastatin is lipophilic, but is scarcely metabolized by CYPs.
Localization (metabolized) of CYP3A4 in liver
11) Confidence 0.20 Published 2009 Journal Vascular Health and Risk Management Section Body Doc Link PMC2788597 Disease Relevance 0.26 Pain Relevance 0.19
It is metabolized by the cytochrome P450 enzymes CYP2D6 and CYP3A4 and may interact with drugs that inhibit these enzymes, such as cimetidine, ketoconazole, paroxetine, fluoxetine, and fluvoxamine.
Localization (metabolized) of CYP3A4 associated with fluoxetine
12) Confidence 0.19 Published 2007 Journal Current Genomics Section Body Doc Link PMC2647161 Disease Relevance 0.11 Pain Relevance 0.18
Imatinib is metabolized mainly by CYP3A4 or CYP3A5 and can competitively inhibit the metabolism of drugs that are CYP3A4 or CYP3A5 substrates.
Localization (metabolized) of CYP3A4
13) Confidence 0.16 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.33 Pain Relevance 0.07
Posaconazole may also increase concentrations of vinca alkaloids, digoxin, HMG-CoA reductase inhibitors metabolized by CYP3A4, and calcium channel blockers metabolized by CYP3A4.7
Localization (metabolized) of CYP3A4 associated with calcium channel
14) Confidence 0.15 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2990390 Disease Relevance 0.28 Pain Relevance 0.08
Posaconazole may also increase concentrations of vinca alkaloids, digoxin, HMG-CoA reductase inhibitors metabolized by CYP3A4, and calcium channel blockers metabolized by CYP3A4.7
Localization (metabolized) of CYP3A4 associated with calcium channel
15) Confidence 0.15 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2990390 Disease Relevance 0.28 Pain Relevance 0.08
Donepezil potentially may interact with drugs metabolized via CYP1A2-, CYP2D6-, and CYP3A4-related enzymes; however, formal pharmacokinetic studies have revealed no clinically meaningful interactions with memantine, risperidone, sertraline, carbidopa/levodopa, theophylline, furosemide, cimetidine, warfarin, and digoxin (Tiseo et al 1998a, b, c, d, e, f; Seltzer 2005).
Localization (metabolized) of CYP3A4
16) Confidence 0.15 Published 2007 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2654795 Disease Relevance 0 Pain Relevance 0.03
For statins metabolized by cytochrome P450 3A4 (CYP3A4), such as lovastatin, atorvastatin, and simvastatin), the incidence was 4.2 per 100,000 person-years.
Localization (metabolized) of CYP3A4
17) Confidence 0.08 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496987 Disease Relevance 0.66 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox